Testing for PD-L1 tumour expression using a validated test is recommended for patients with advanced or metastatic NSCLC.1
When assessing the PD-L1 status of the tumour, it is important that a well-validated and robust methodology is chosen to minimise false negative or false positive determinations.1
Tissue based PD-L1 expression is the first criterion for the prediction of ICI treatment. The expression of PD-L1 on tumor cells has been demonstrated to be associated with the efficacy of PD-1/PD-L1 blockade therapy in NSCLC.2
